• Genetic TherapyEnrolling

  Study of ARCT-032 in adults with cystic fibrosis who are not on CFTR modulator therapy. , protocol number Arcturus ARCT-032-02 Cohort 4

  This study will test the safety, tolerability and effectiveness of ARCT-032, a nebulized therapy intended to deliver a new, correct copy of CFTR messenger RNA (mRNA) to cells.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    45 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    24 weeks

• Anti-InfectiveEnrolling

  ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM) , protocol number ABATE-IP-18

  This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of IV gallium, a drug intended to treat infections in the lung.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25% or greater

  • Number of Visits:

    8

  • Length of Participation:

    20 weeks

• Nutritional-GIEnrolling

  Study of new enzyme therapy NHS7108 in Adults With Exocrine Pancreatic Insufficiency , protocol number Nestle 2307CLI

  This study will assess the safety and effectiveness of NHS7108 to see how it works compared to the approved pancreatic enzyme replacement therapy Zenpep in adults with pancreatic insufficiency.

  • Age:

    18 Years to 85 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    8

  • Length of Participation:

    10 weeks

• ObservationalEnrolling

  REACH: An observational study for people with CF who do not take CFTR modulators , protocol number REACH-OB-23

  The REACH observational study will collect health information on people with CF 12 years and older who do not take CFTR modulators.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    12 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.